PMID- 36059699
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220907
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world 
      study based on the FDA adverse event reporting system database.
PG  - 941079
LID - 10.3389/fonc.2022.941079 [doi]
LID - 941079
AB  - BACKGROUND: Immune checkpoint inhibitors (ICIs), the treatment of multiple cancer 
      types, can be associated with respiratory system adverse events (AEs). The aim of 
      this study is to quantify the association of respiratory system AEs and ICIs and 
      to characterize the profiles of ICI-related respiratory system complications from 
      Food and Drug Administration Adverse Event Reporting System (FAERS) data. 
      METHODS: The disproportionality of respiratory system AE-related ICIs based on 
      FAERS data from January 2014 to September 2021 was analyzed using the reporting 
      odds ratio (ROR) and information component (IC) as measures of potential risk 
      increase. RESULTS: A total of 38,415,849 records were involved; among these, 
      36,923 records related to respiratory system AEs after ICI treatment were 
      identified. In the first 3 months, the cumulative proportion of respiratory 
      system AEs was 75.40%. Men had a slightly higher reporting frequency than that of 
      women (ROR = 1.74, 95% CI: 1.70-1.78). Death cases had a slightly higher 
      reporting frequency in ICI-associated respiratory system AEs than that of other 
      drug-associated respiratory system AEs (ROR = 1.40, 95% CI: 1.38-1.41). 
      Anti-programmed cell death 1 (PD-1) drugs and anti-programmed cell death ligand 1 
      (PD-L1) drugs were significantly associated with respiratory system toxicities. 
      However, anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) drugs did not 
      demonstrate an association with respiratory system toxicities. Interstitial lung 
      disease and pneumonitis were found to be significantly associated with all eight 
      types of ICIs. In addition, 7 in 10 class-specific respiratory system AEs (lower 
      respiratory tract disorders, pleural disorders, pulmonary vascular disorders, 
      respiratory disorders not elsewhere classified (NEC), respiratory tract 
      infections, respiratory tract neoplasms, and thoracic disorders) were associated 
      with ICIs. The signal values of IC(025) were from 0.08 to 2.66. CONCLUSIONS: 
      Overall, this study showed a high reporting frequency of respiratory system 
      toxicities caused by ICIs. Early recognition and management of ICI-related 
      respiratory system AEs are of vital importance in practice. Maximizing the 
      benefit while reducing potential respiratory system toxicities of ICIs should 
      become a priority.
CI  - Copyright (c) 2022 Cui, Deng, Wang, Ren, Wang and Cui.
FAU - Cui, Chanjuan
AU  - Cui C
AD  - Department of Laboratory Medicine, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Deng, Lei
AU  - Deng L
AD  - Department of Radiation Oncology, National Cancer Center and Cancer Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Wang, Wenqing
AU  - Wang W
AD  - Department of Radiation Oncology, National Cancer Center and Cancer Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Ren, Xiayang
AU  - Ren X
AD  - Department of Pharmacy, National Cancer Center and Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Wang, Yanfeng
AU  - Wang Y
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Cui, Wei
AU  - Cui W
AD  - Department of Laboratory Medicine, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20220819
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9437516
OTO - NOTNLM
OT  - adverse events
OT  - cancer
OT  - faers
OT  - immune checkpoint inhibitors
OT  - respiratory system
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/06 06:00
MHDA- 2022/09/06 06:01
PMCR- 2022/01/01
CRDT- 2022/09/05 03:41
PHST- 2022/05/11 00:00 [received]
PHST- 2022/07/28 00:00 [accepted]
PHST- 2022/09/05 03:41 [entrez]
PHST- 2022/09/06 06:00 [pubmed]
PHST- 2022/09/06 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.941079 [doi]
PST - epublish
SO  - Front Oncol. 2022 Aug 19;12:941079. doi: 10.3389/fonc.2022.941079. eCollection 
      2022.